Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 700 across all filing types
Latest filing 2016-05-04 Interim / Quarterly Rep…
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2016
2016-05-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 4, 2016, by Flex Pharma, Inc. It specifically references Item 2.02 "Results of Operations and Financial Condition" and states that a press release announcing financial results for the quarter ended March 31, 2016, is attached as Exhibit 99.1. The document itself is a current report announcing the earnings release, not the earnings release report itself. The text explicitly says the press release is attached and incorporated by reference, and the 8-K is furnishing this information. The document length is 2894 characters, which is short and consistent with an announcement rather than a full earnings report. According to the rules, such a document is classified as an Earnings Release (ER) because it announces quarterly financial results. The 8-K with Item 2.02 is commonly used for earnings releases. Therefore, the correct classification is ER with high confidence.
2016-05-04 English
DEF 14A
Proxy Solicitation & Information Statement
2016-04-28 English
Regulatory Filings 2016
Regulatory Filings
2016-04-27 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting the effectiveness of a Registration Statement on Form S-3. It is a formal correspondence related to a regulatory filing process, specifically about the registration statement becoming effective. The document does not contain financial data, report content, or detailed disclosures itself, but rather is a procedural request. The length is short (1633 characters), and it is clearly not a full report but an announcement/request related to a filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2016-04-22 English
8-K
Investor Presentation Classification · 90% confidence The document is a Form 8-K current report filed with the SEC, dated April 19, 2016. It announces that Flex Pharma, Inc. will present a poster and a presentation at the Annual Meeting of the American Academy of Neurology. The content described includes a poster and a presentation related to a clinical trial. The document explicitly states these materials are furnished as exhibits. The length of the document is 4085 characters, which is relatively short and mainly serves as an announcement of the presentation materials rather than the materials themselves. The key phrase 'will present a poster and provide a presentation' and the fact that these are attached as exhibits indicate this is an announcement of investor or scientific presentation materials. This fits the definition of an Investor Presentation (IP) filing, which includes detailed presentations for investors focusing on financials, strategy, and market position, or in this case, scientific presentation relevant to investors. It is not an Annual Report, Earnings Release, or other financial report. It is not a Regulatory Filing (RNS) because it is a formal 8-K filing with substantive content about the presentation. Therefore, the best classification is Investor Presentation (IP).
2016-04-19 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.